Approved liraglutide-based combination products include Alina 30, developed for these therapies for diabetes, as well as Alina 50 for weight management applications. Both variants come as part of the company’s broader Alina variable-dose pen injector platform. The platform offers multiple pre-configured variants for GLP-1s and other injectable therapies.
Alina features a dial-a-dose mechanism with visual, audible and tactile feedback during dose selection and injection. Stevanato Group also made it compatible with ISO standard 3 mL glass cartridges. The company said its platform supports manufacturing scalability and integration into existing pharmaceutical fill-finish and final assembly supply chains.
Stevanato Group said its authorizations come as injectable therapies — especially GLP-1s — play an increasingly important role in healthcare. The company believes its Alina portfolio, along side its other pen injectors and on-body devices, can help expand its drug delivery capabilities.
Michele Monico, President of Drug Delivery Systems & In Vitro Diagnostics at Stevanato Group, said:
“We are pleased to see Alina incorporated into liraglutide-based therapies that have received marketing authorizations in multiple European markets. This achievement highlights our commitment to support customers throughout their product journey, from development to commercialization. As demand for treatments addressing diabetes and weight management continues to grow, we are proud to provide drug delivery solutions that help enable broader patient access to these therapies.
“Drug delivery systems are playing an increasingly strategic role in the success of injectable therapies. The rapid growth of biologics, GLP-1 therapies, and self-administration is reshaping how pharmaceutical companies approach product development and commercialization. As a result, demand is increasing for integrated solutions that combine device innovation, manufacturing expertise, and supply chain reliability. We believe our broad portfolio of drug delivery platforms, supported by our end-to-end capabilities, positions Stevanato Group well to support this evolution.”
